Taysha Gene Therapies, Inc. (TSHA)Healthcare | Biotechnology | Dallas, United States | NasdaqGS
3.62 USD
-0.52
(-12.576%) ⇩
(Oct. 13, 2026, 2:16 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 10:04 a.m. EDT
The long-term outlook remains deeply precarious due to the company's burning cash and negative earnings, despite a recent price rebound that has erased some of the massive historical losses. While the balance sheet currently appears robust relative to debt, the relentless free cash flow burn and lack of profitability suggest the business is still in a high-risk survival phase dependent on future capital raises or clinical milestones. The recent price surge is likely driven by specific trial data or a public offering, creating a fragile 'dead cat bounce' rather than a sustainable recovery. Short-term momentum is weak, with the stock trading well below its moving averages and facing significant resistance from the recent highs. The options market confirms this hesitation, with traders buying insurance against further declines while waiting for a catalyst to justify a move higher. Until the path to profitability or a definitive commercial launch is clear, the risk-reward profile favors caution over conviction. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.078660 |
| AutoETS | 0.079426 |
| AutoARIMA | 0.079426 |
| AutoTheta | 0.101068 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 2.47 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.367 |
| Excess Kurtosis | -0.76 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 14.645 |
| Revenue per Share | 0.015 |
| Market Cap | 1,179,517,312 |
| Forward P/E | -7.83 |
| Beta | 1.17 |
| Website | https://www.tayshagtx.com |
As of Oct. 10, 2026, 10:04 a.m. EDT: Speculators are positioning defensively with heavy put volume at strikes below the current price, particularly for the December expiration where deep out-of-the-money puts show significant open interest. Conversely, call activity is concentrated far out-of-the-money (OTM) at strikes significantly above the current level, indicating a speculative bet on a binary event or recovery rather than a near-term trend. The implied volatility surface shows elevated premiums for downside protection compared to upside potential.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.1968962 |
| Address1 | 3,000 Pegasus Park Drive |
| Address2 | Suite 1430 |
| All Time High | 33.35 |
| All Time Low | 0.5 |
| Ask | 4.56 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 4,454,140 |
| Average Daily Volume3 Month | 3,287,581 |
| Average Volume | 3,287,581 |
| Average Volume10Days | 4,454,140 |
| Beta | 1.172 |
| Bid | 2.92 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 1.19 |
| City | Dallas |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.62 |
| Current Ratio | 17.765 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 4.13 |
| Day Low | 3.55 |
| Debt To Equity | 14.645 |
| Display Name | Taysha Gene Therapies |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,478,400 |
| Earnings Call Timestamp Start | 1,786,478,400 |
| Earnings Timestamp | 1,786,478,400 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | -151,988,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.252 |
| Enterprise To Revenue | 173.247 |
| Enterprise Value | 950,257,856 |
| Eps Current Year | -0.474 |
| Eps Forward | -0.4625 |
| Eps Trailing Twelve Months | -0.41 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.4673 |
| Fifty Day Average Change | -1.8473 |
| Fifty Day Average Change Percent | -0.3378816 |
| Fifty Two Week Change Percent | -19.68962 |
| Fifty Two Week High | 7.3 |
| Fifty Two Week High Change | -3.6800003 |
| Fifty Two Week High Change Percent | -0.5041096 |
| Fifty Two Week Low | 3.55 |
| Fifty Two Week Low Change | 0.06999993 |
| Fifty Two Week Low Change Percent | 0.019718291 |
| Fifty Two Week Range | 3.55 - 7.3 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,600,954,200,000 |
| Float Shares | 232,619,084 |
| Forward Eps | -0.4625 |
| Forward P E | -7.827027 |
| Free Cashflow | -80,965,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 99 |
| Fullday Change | -0.52 |
| Fullday Change Percent | -12.575574 |
| Fullday Price | 3.62 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 1.0 |
| Gross Profits | 5,485,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.094469994 |
| Held Percent Institutions | 0.94249 |
| Implied Shares Outstanding | 325,833,545 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-09-24 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. |
| Long Name | Taysha Gene Therapies, Inc. |
| Market | us_market |
| Market Cap | 1,179,517,312 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_665948579 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -149,632,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,599,842,705 |
| Number Of Analyst Opinions | 13 |
| Open | 4.09 |
| Operating Cashflow | -132,191,000 |
| Operating Margins | -27.92325 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 214 612 0000 |
| Previous Close | 4.14 |
| Price Eps Current Year | -7.6371303 |
| Price Hint | 4 |
| Price To Book | 3.0420165 |
| Price To Sales Trailing12 Months | 215.04417 |
| Profit Margins | 0.0 |
| Quick Ratio | 17.533 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.52 |
| Regular Market Change Percent | -12.575574 |
| Regular Market Day High | 4.13 |
| Regular Market Day Low | 3.55 |
| Regular Market Day Range | 3.55 - 4.13 |
| Regular Market Open | 4.09 |
| Regular Market Previous Close | 4.14 |
| Regular Market Price | 3.62 |
| Regular Market Time | 1,791,915,386 |
| Regular Market Volume | 2,810,890 |
| Return On Assets | -0.23819 |
| Return On Equity | -0.47055 |
| Revenue Per Share | 0.015 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 325,833,545 |
| Shares Percent Shares Out | 0.1689 |
| Shares Short | 55,020,663 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 46,800,424 |
| Short Name | Taysha Gene Therapies, Inc. |
| Short Percent Of Float | 0.1715 |
| Short Ratio | 14.29 |
| Source Interval | 15 |
| State | TX |
| Symbol | TSHA |
| Target High Price | 19.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 13.0 |
| Target Median Price | 12.0 |
| Total Cash | 455,407,008 |
| Total Cash Per Share | 1.398 |
| Total Debt | 56,714,000 |
| Total Revenue | 5,485,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.41 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.418475 |
| Two Hundred Day Average Change | -1.7984753 |
| Two Hundred Day Average Change Percent | -0.33191538 |
| Type Disp | Equity |
| Volume | 2,810,890 |
| Website | https://www.tayshagtx.com |
| Zip | 75,247 |